Common Contracts
46 similar Underwriting Agreement contracts by TherapeuticsMD, Inc., Fulcrum Therapeutics, Inc., Idera Pharmaceuticals, Inc., others
Karuna Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 22nd, 2023 • Karuna Therapeutics, Inc. • Pharmaceutical preparations
Karuna Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of 2,479,391 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 371,908 additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • January 18th, 2023 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,615,384 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,442,307 additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • August 17th, 2022 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • New York
Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,590,792 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,438,618 additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Maxar Technologies Inc. 10,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 22nd, 2021 • Maxar Technologies Inc. • Radio & tv broadcasting & communications equipment • New York
Maxar Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (collectively, the “Underwriters”) an aggregate of 10,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 1,500,000 additional shares (the “Optional Securities”) of Common Stock, par value $0.0001 per share, of the Company (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
Underwriting AgreementUnderwriting Agreement • March 19th, 2021 • Primoris Services Corp • Water, sewer, pipeline, comm & power line construction • New York
Primoris Services Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,500,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 675,000 additional shares (the “Optional Securities”) of common stock, $0.0001 par value per share (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 16th, 2021 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto, if any (the “Underwriters”), for whom Cantor Fitzgerald & Co. is acting as representative (the “Representative”, “you” or “your”), an aggregate of 59,459,460 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 8,918,919 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 13th, 2020 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom Cantor Fitzgerald & Co. is acting as representative (the “Representative”, “you” or “your”), an aggregate of 23,437,500 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 3,515,625 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Stewart Information Services Corporation 2,631,600 Shares Common Stock, Par Value $1.00 per Share Underwriting AgreementUnderwriting Agreement • August 17th, 2020 • Stewart Information Services Corp • Title insurance • New York
The primary purpose of our professional engagement was not to establish or confirm factual matters or financial, accounting or quantitative information. Furthermore, many determinations involved in the preparation of the Registration Statement, the Disclosure Package and the Prospectus are of a wholly or partially non-legal character or relate to legal matters outside the scope of our opinion separately delivered to you today in respect of certain matters under the laws of the State of New York, the federal laws of the United States of America and the General Corporation Law of the State of Delaware. As a result, we are not passing upon, and do not assume any responsibility for, the accuracy, completeness or fairness of the statements contained in the Registration Statement, the Disclosure Package or the Prospectus, and we have not ourselves checked the accuracy, completeness or fairness of, or otherwise verified, the information furnished in such documents (except to the extent expres
Flexion Therapeutics, Inc. 9,230,770 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • May 21st, 2020 • Flexion Therapeutics Inc • Pharmaceutical preparations • New York
Flexion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 9,230,770 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,384,615 additional shares (the “Optional Shares”) of the Company’s common stock, $0.001 par value per share (“Stock”) (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Zillow Group, Inc. Class C Capital Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • May 14th, 2020 • Zillow Group, Inc. • Services-business services, nec • New York
Zillow Group, Inc., a corporation organized under the laws of Washington (the “Company”), proposes, subject to the terms and conditions in this underwriting agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and Citigroup Global Markets Inc. are acting as representatives (the “Representatives”), an aggregate of 8,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to an aggregate of 1,200,000 additional shares (the “Optional Securities”) of Class C capital stock of the Company, par value $0.0001 per share (“Stock”). The Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively referred to as the “Securities”.
Underwriting AgreementUnderwriting Agreement • January 27th, 2020 • Elanco Animal Health Inc • Pharmaceutical preparations • New York
Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 22,694,732 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,269,473 additional shares (the “Optional Shares”) of common stock, no par value (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 29th, 2019 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom J.P. Morgan Securities LLC is acting as representative (the “Representative”, “you” or “your”), an aggregate of 26,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 3,900,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
uniQure N.V. 4,891,305 Ordinary Shares (Nominal Value € 0.05 Per Share) Underwriting AgreementUnderwriting Agreement • September 6th, 2019 • uniQure N.V. • Pharmaceutical preparations • New York
uniQure N.V., a Dutch public company with limited liability (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,891,305 ordinary shares (the “Firm Securities”) and, at the election of the Underwriters, up to 733,695 additional ordinary shares (the “Optional Securities”), nominal value €0.05 per share (“Ordinary Shares”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
Underwriting AgreementUnderwriting Agreement • May 13th, 2019 • BICYCLE THERAPEUTICS LTD • Pharmaceutical preparations
Bicycle Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), and in the manner contemplated by the Agreement, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of [·] American Depositary Shares representing [·] Ordinary Shares nominal value £0.01 per share (the “Ordinary Shares”) and, at the election of the Underwriters, up to [·] additional American Depositary Shares representing [·] Ordinary Shares. The aggregate of [·] American Depositary Shares representing [·] Ordinary Shares to be sold by the Company is herein called the “Firm ADSs”, and the aggregate of [·] American Depositary Shares representing [·] additional Ordinary Shares to be sold by the Company is called the “Optional ADSs”. The Firm ADSs and the Optional
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • August 3rd, 2018 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom Goldman Sachs & Co. LLC is acting as representative (the “Representative”, “you” or “your”), an aggregate of 12,745,098 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,911,764 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Zillow Group, Inc. Class C Capital Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • June 29th, 2018 • Zillow Group, Inc. • Services-business services, nec • New York
Zillow Group, Inc., a corporation organized under the laws of Washington (the “Company”), proposes, subject to the terms and conditions in this underwriting agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC and Citigroup Global Markets Inc. are acting as representatives (the “Representatives”), an aggregate of 5,701,754 shares (the “Firm Securities”) and, at the election of the Underwriters, up to an aggregate of 855,263 additional shares (the “Optional Securities”) of Class C Capital Stock of the Company, par value $0.0001 per share (“Stock”). The Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively referred to as the “Securities”.
Idera Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 26th, 2017 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 33,333,334 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 5,000,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
KMG Chemicals, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • October 20th, 2017 • KMG Chemicals Inc • Chemicals & allied products • New York
KMG Chemicals, Inc., a Texas corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 450,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.01 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively referred to as the “Shares”).
Radcom Ltd. Ordinary Shares, par value NIS 0.20 per share Underwriting AgreementUnderwriting Agreement • October 19th, 2017 • Radcom LTD • Computer peripheral equipment, nec • New York
Radcom Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 1,444,814 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 216,722 additional shares (the “Optional Securities”) of Ordinary Shares, par value NIS 0.20 per share (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
Beacon Roofing Supply, Inc. 6,325,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 25th, 2017 • Beacon Roofing Supply Inc • Wholesale-lumber & other construction materials • New York
The Company has entered into a Stock Purchase Agreement, dated as of August 24, 2017, as amended and supplemented from time to time (including all exhibits, schedules and attachments thereto, the “Acquisition Agreement”), among the Company, Oldcastle, Inc., a Delaware corporation (“Allied Parent”), and Oldcastle Distribution, Inc., a Delaware corporation (“Allied Seller”), pursuant to which the Company will acquire 100% of the outstanding capital stock of Allied Building Products Corp., a New Jersey corporation (“Allied”), and Kapalama Kilgos Acquisition Corp., a Delaware corporation (“Kilauea” and, together with Allied and its and their respective subsidiaries, being hereinafter called the “Acquired Company”), after the offering of the Shares hereunder.
Underwriting AgreementUnderwriting Agreement • August 11th, 2017 • BioAmber Inc. • Industrial organic chemicals • New York
BioAmber Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters signatory hereto and named in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 14,666,667 combinations each consisting of one share (the “Firm Shares”) of Common Stock, par value $0.01 per share (“Stock”), of the Company and one warrant to purchase one share of Common Stock as set forth in the Prospectus (as defined herein) (the “Firm Warrants”). The Firm Shares and the Option Shares (as defined herein) that that the Underwriters elect to purchase pursuant to Section 2 hereof are also sometimes collectively referred to as the “Shares” and the Firm Warrants and the Option Warrants (as defined herein) are also sometimes collectively referred to herein as the “Warrants”. The Shares and the Warrants are sometimes referred to as the “Securities”. To the extent there a
FibroGen, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • April 6th, 2017 • Fibrogen Inc • Pharmaceutical preparations • New York
FibroGen, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,228,750 shares (the “Shares”) of Common Stock, par value $0.01 per share (the “Stock”) of the Company.
Underwriting AgreementUnderwriting Agreement • March 31st, 2017 • STORE CAPITAL Corp • Real estate investment trusts • New York
STORE Capital Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (collectively, the “Underwriters,” and, individually, an “Underwriter”), for whom you are acting as representatives (in such capacity, the “Representatives”), an aggregate of 8,650,000 shares (the “Firm Shares”), and, at the election of the Underwriters, up to 1,297,500 additional shares (the “Optional Shares”), of Common Stock, $0.01 par value per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
Radcom Ltd. Ordinary Shares, par value NIS 0.20 per share Underwriting AgreementUnderwriting Agreement • May 20th, 2016 • Radcom LTD • Computer peripheral equipment, nec • New York
Radcom Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”) an aggregate of 1,818,182 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 272,727 additional shares (the “Optional Securities”) of Ordinary Shares, par value NIS 0.20 per share (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 12th, 2016 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom Goldman, Sachs & Co. and Cowen and Company, LLC are acting as representatives (together, the “Representatives”, “you” or “your”), an aggregate of 15,151,515 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,272,727 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
TETRALOGIC PHARMACEUTICALS CORPORATION Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • May 1st, 2015 • Tetralogic Pharmaceuticals Corp • Pharmaceutical preparations • New York
TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom William Blair & Company, L.L.C. and Nomura Securities International, Inc. are acting as representatives (the “Representatives” or “you”) an aggregate of 6,250,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 937,500 additional shares (the “Optional Securities”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
Idera Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 13th, 2015 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 20,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 3,000,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Common Stock, par value $0.001 per share Warrants to Purchase Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 6th, 2015 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written consent of the Representative, provided that (1) the Representative receives a signed lock-up agreement for the balance of the lockup period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value, (3) such transfers are not required to be reported with the Securities and Exchange Commission in accordance with the Securities Exchange Act of 1934, as amended the (“Exchange Act”) under Section 16 or otherwise, and (4) neither the undersigned nor any donee, trustee, distributee or transferee, as the case may be, otherwise voluntarily effects any public filing or report or other public notice regarding such transfers:
TherapeuticsMD, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • August 4th, 2014 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
TherapeuticsMD, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated in this Underwriting Agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom Goldman, Sachs & Co. are acting as representative (the “Representative”, “you” or “your”), an aggregate of 8,565,310 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 1,284,796 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 per share (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Darling International Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • December 13th, 2013 • Darling International Inc • Fats & oils • New York
Darling International Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 40,000,000 shares (the “Firm Shares”) of common stock, par value $0.01 per share (“Stock”) of the Company and, at the election of the Underwriters, up to 6,000,000 additional shares (the “Optional Shares”) of Stock of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
Tesla Motors, Inc. Common Stock, par value $0.001 Underwriting AgreementUnderwriting Agreement • May 20th, 2013 • Tesla Motors Inc • Motor vehicles & passenger car bodies • New York
Tesla Motors, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman, Sachs & Co. (“you” or the “Underwriters”) an aggregate of 3,393,793 shares, par value $0.001 (“Stock”) of the Company (the “Firm Shares”) and, at your election, up to 509,069 additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriter elects to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”).
Underwriting AgreementUnderwriting Agreement • November 30th, 2012 • Clean Harbors Inc • Hazardous waste management • New York
Clean Harbors, Inc, a Massachusetts corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,000,000 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 900,000 additional shares (the “Optional Securities”) of common stock (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
Tesla Motors, Inc. Common Stock, par value $0.001 Form of Underwriting AgreementUnderwriting Agreement • September 28th, 2012 • Tesla Motors Inc • Motor vehicles & passenger car bodies • New York
Tesla Motors, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman, Sachs & Co. (“you” or the “Underwriter”) an aggregate of shares, par value $0.001 (“Stock”) of the Company (the “Firm Shares”) and, at your election, up to additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriter elects to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”).
TriMas Corporation Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • May 8th, 2012 • Trimas Corp • Metal forgings & stampings • New York
TriMas Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representatives”) an aggregate of 4,000,000 shares and, at the election of the Underwriters, up to 600,000 additional shares of Common Stock, par value $0.01 per share (“Stock”) of the Company. The aggregate of 4,000,000 shares to be sold by the Company is herein called the “Firm Shares” and the aggregate of 600,000 additional shares to be sold by the Company is herein called the “Optional Shares”. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
GCT Semiconductor, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • February 15th, 2012 • GCT Semiconductor Inc • Semiconductors & related devices • New York
GCT Semiconductor, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ ] additional shares (the “Optional Shares”) of Common Stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
